WilmerHale Advises Akebia Therapeutics in $140 Million Senior Secured Term Loan Facility

WilmerHale Advises Akebia Therapeutics in $140 Million Senior Secured Term Loan Facility

Client News

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, announced that it has entered into a senior secured term loan facility with Symbiotic Capital providing for up to $140 million in financing. The facility provided an initial funded tranche of $60 million and the ability to request up to $80 million of additional discretionary term loans. Proceeds of the initial term loan were used to repay Akebia’s existing term loan facility.

WilmerHale advised Akebia on the transaction.

The WilmerHale team was led by Brandt Tierney and Caroline Dotolo and included Elizabeth Greene and Sophie Bonadeo, with additional assistance from Meghan Walsh, Amanda Albert, Jeff Johnson, Tim Silva, Mykaila Delesdernier, Sara Gardner, and Nick Goodwin.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.